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Introduction
Cocaine is a well-known, widely abused drug (UNODC, 2010) . There is no FDA-approved medication specific for cocaine abuse treatment. The disastrous medical and social consequences of cocaine abuse have made a high priority the development of an anti-cocaine medication (Karila et al., 2008; Xi and Gardner, 2008) . It would be an ideal anti-cocaine medication to accelerate cocaine metabolism producing biologically inactive metabolites via a route similar to the primary cocaine-metabolizing pathway, i.e. cocaine hydrolysis catalyzed by butyrylcholinesterase (BChE) in plasma (Carrera et al., 2004; Gorelick, 2008; Kamendulis et al., 1996; Landry et al., 1993; Meijler et al., 2005; . Unfortunately, wild-type BChE has a low catalytic activity against naturally occurring (-)-cocaine (k cat = 4.1 min -1 and K M = 4.5 μM) (Darvesh et al., 2003; Gatley, 1991; Giacobini, 2003; Hamza et al., 2005; Sun et al., 2002a) . It is interesting to design human BChE mutants that may be regarded as a cocaine hydrolase (CocH), with a significantly improved catalytic activity against (-)-cocaine.
It has been well-known that computational design of high-activity mutants of an enzyme is extremely challenging, particularly when the chemical reaction process is rate-determining for the enzymatic reaction (Gao et al., 2006; Gao and Zhan, 2006) . Generally speaking, for computational design of a mutant enzyme with an improved catalytic activity for a given substrate, one needs to design possible amino-acid mutations that can accelerate the ratedetermining step of the catalytic reaction process (Hamza et al., 2005; Zhan and Gao, 2005; Zhan et al., 2003) while other steps of the reaction are not slowed down by the mutations. The detailed reaction pathway for BChE-catalyzed hydrolysis of (-)-cocaine was uncovered by extensive molecular dynamics (MD) simulations (Hamza et al., 2005; Zhan et al., 2003) and reaction coordinate calculations Zhan et al., 2003) using quantum mechanics (QM) MOL #68494
In Vitro Activity Tests
Materials. Cloned pfu DNA polymerase and Dpn I endonuclease were obtained from Stratagene (La Jolla, CA). Site-directed Mutagenesis. Site-directed mutagenesis of human BChE cDNA was performed by using the QuikChange method (Braman et al., 2000) . Further mutation(s) required to produce a new BChE mutant cDNA was/were generated from the cDNA corresponding to the A199S/S287G/A328W/Y332G mutant of human BChE in a pRc/CMV expression plasmid (Masson et al., 1999 occasional stirring for one hour. More than 95% enzyme activity was found to bind to the resin after this incubation. The suspension was then packed in a column (5 × 50 cm) and the medium was allowed to flow through rapidly with the aid of suction (50-100 ml/min). The QFF resin was repacked again in a washing buffer after all of the medium was excluded. Data analysis. Data from the behavioral toxicity studies (i.e. % of mice showing affected responses) were analyzed with Fisher's exact probability test. Protective effects of the BChE mutant were compared with those of phosphate buffered saline. The criterion for significance was set at p<0.05. The value of ED 100conv was determined when 100% of mice showed convulsions. Such value was used to compare the degree of shifts of cocaine's dose-response curve in subjects pretreated with different BChE mutants.
Results
BChE Mutant Design: Insights from Molecular Modeling. Our goal of the present study was to identify BChE mutants that have significantly improved catalytic activity against (-)-cocaine, without a significant change in the catalytic activity against ACh, compared to wildtype BChE in order to make sure that the cocaine detoxification with BChE mutants will not affect the cholinergic transmission. Based on the catalytic mechanisms for BChE-catalyzed hydrolyses of (-)-cocaine and ACh shown in Figure 1 (A) and (B) (Gao et al., 2006; This article has not been copyedited and formatted. The final version may differ from this version. Gao and Zhan, 2006; Zhan and Gao, 2005; Zhan et al., 2003) , our rational design of BChE mutants in this study was focused on the hydrogen bonding interactions between the carbonyl oxygen of the substrate and the oxyanion hole. Our previous computational studies (Gao et al., 2006; Gao and Zhan, 2006; Zhan and Gao, 2005; Zhan et al., 2003) have revealed that the fundamental reaction pathway for BChE-catalyzed hydrolysis of (-)-cocaine is similar to that for BChE-catalyzed hydrolysis of ACh in terms of the formation and breaking of covalent bonds during the reaction processes. As shown in Figure 1 Figure 2 are the measured kinetic data. Summarized in Table 1 are the determined kinetic parameters.
The three mutants of human BChE collected in Table 1 This article has not been copyedited and formatted. The final version may differ from this version. Further, as seen in Table 1 , the catalytic efficiency of wild-type BChE against ACh (k cat /K M = 5.8 × 10 8 M -1 min -1 ) is ~640-fold higher than that of the same enzyme against (-)-cocaine (k cat /K M = 9.1 × 10 5 M -1 min -1 ). However, it is interesting to note that, for each of the three BChE mutants, the catalytic efficiency against (-)-cocaine (k cat /K M = 9.9 × 10 8 -1.6 × 10 9 M -1 min -1 ) becomes significantly higher than that of any enzyme (wild-type BChE or mutant) in Table 1 against ACh (k cat /K M = 1.8 -5.8 × 10 8 M -1 min -1 ). These BChE mutants not only have a considerably improved catalytic efficiency against (-)-cocaine, but also have the desirable selectivity for (-)-cocaine over ACh.
In Vivo Activity of the BChE Mutants in Protection of
Mice from Cocaine Toxicity. The in vitro activity data discussed above suggest that all of the three BChE mutants have the desirable high catalytic efficiency and substrate selectivity for (-)-cocaine. Within the three promising BChE mutants, we expressed and purified the A199S/S287G/A328W/Y332G and A199S/F227A/S287G/A328W/E441D mutants in large-scale for the purpose of in vivo studies.
We are interested in testing these two representative mutants in vivo because these two mutants both have their own unique mutation(s): Y332G mutation in the A199S/S287G/A328W/Y332G mutant; F227A and E441D mutations in the A199S/F227A/S287G/A328W/E441D mutant. It is interesting to know which mutant is actually more potent in the practical detoxification of cocaine.
This article has not been copyedited and formatted. The final version may differ from this version. For the large-scale expression and purification of these two BChE mutants, we developed the stable cell lines in 293F by using lentivirus plasmids encoding the cDNAs of the BChE mutants. Each mutant enzyme was purified by using an ion exchanger and adsorption chromatographies. The catalytic activities of the purified enzymes were confirmed by using the same in vitro assays mentioned above.
The purified mutant enzymes were used to study their in vivo activity in protection of male NIH-Swiss mice (27 -30 g) from acute toxicity of a lethal dose of cocaine (180 mg/kg). Figure 3 compares the protective effects of the BChE mutants. Intraperitoneal administration of cocaine 180 mg/kg produced convulsions and lethality in all tested mice (n=8). Pretreatment with the BChE mutant (i.e. 1 min prior to cocaine administration) dose-dependently protected mice against cocaine-induced convulsions and lethality. In particular, the A199S/S287G/A328W/Y332G mutant of human BChE at the dose of 0.03 mg produced full protection in mice after receiving a lethal dose of cocaine 180 mg/kg (p<0.05). The A199S/F227A/S287G/A328W/E441D mutant of human BChE was more potent than the A199S/S287G/A328W/Y332G mutant. As seen in Figure  3 , the A199S/F227A/S287G/A328W/E441D mutant at 0.02 mg also produced full protection in mice after receiving a lethal dose of cocaine 180 mg/kg (p<0.05). So, the minimum dose of the enzyme required to produce full protection of the mice from the acute toxicity of 180 mg/kg cocaine was determined to be 0.03 mg for the A199S/S287G/A328W/Y332G mutant and 0.02 mg for the A199S/F227A/S287G/A328W/E441D mutant.
Discussion
The present study accounting for the mutation-caused changes of the catalytic activities of These mutants of human BChE provided significantly better in vivo protection of mice from the acute cocaine toxicity than the well-known cocaine esterase (CocE) and its mutants reported to date (Brim et al., 2010; Collins et al., 2009; Cooper et al., 2006; Gao et al., 2009; Ko et al., 2007; Narasimhan et al., 2010) . The in vivo potency of these two mutants is roughly equivalent to that of the previously reported most efficient cocaine hydrolase (Zheng et al., 2008) which also provided the full protection of the mice at a similar dose (0.01 and 0.03 mg). But the present study accounted for the substrate selectivity for the first time.
We are not aware of any study determining whether administration of BChE produces significant decreases in ACh levels. Published case reports on clinical use of partially purified human BChE did not mention any adverse effects related to altered ACh activity (Gorelick, 2008) . On the other hand, it has been known that BChE is over-expressed in Alzheimer's disease (AD) patients (Guillozet et al., 1997) and the presence of BChE with β-amyloid (Aβ) plaques dramatically amplifies the toxicity of Aβ (Barber et al., 1996) . In addition, increased BChE gene expression correlates with neurodegenerative disorders (Mack and Robitzki, 2000) . In light of these published reports, without further studies, we do not know for sure that the administration of a BChE mutant with significantly increased activity against ACh will not cause any unexpected adverse effects for the patients, particularly those who also suffer from AD or other neurodegenerative disorders. In any case, it is reasonable to assume that the administration of a BChE mutant with substrate selectivity for (-)-cocaine over ACh will less-likely cause unexpected adverse effects.
Based on the in vitro activity data, the A199S/S287G/A328W/Y332G mutant has a significantly higher k cat value (3,060 min -1 ) against (-)-cocaine than the A199S/F227A/S287G/A328W/E441D mutant (k cat = 1,730 min -1 ). On the other hand, the than the K M value, the A199S/F227A/S287G/A328W/E441D mutant is expected to be more effective than the A199S/S287G/A328W/Y332G mutant.
The determined relative magnitudes of the minimum doses of the BChE mutants producing the full protection of mice from the acute cocaine toxicity clearly demonstrate that the catalytic efficiency (i.e. the k cat /K M value) of the BChE mutant is the primary factor determining the in vivo potency in the practical protection of the mice from the acute cocaine toxicity, which contrasts with the usual perception that the catalytic rate constant (k cat ) is the primary factor.
Further, due to the fact that the A199S/F227A/S287G/A328W/E441D mutant with a larger k cat /K M value and a smaller k cat value (compared to the A199S/S287G/A328W/Y332G mutant) is more potent in the practical protection of the mice from the acute cocaine toxicity, the cocaine concentration in the blood of mice overdosed with 180 mg/kg cocaine was not higher than K M value (3.1 µM) of the A199S/S287G/A328W/Y332G mutant in the presence of the BChE mutant. In light of this finding, for further improvement of the efficacy in cocaine detoxification, future rational design of new BChE mutants should focus on the k cat /K M value, rather than the k cat value alone. This article has not been copyedited and formatted. The final version may differ from this version. 
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